van der Noord VE - Search Results

1

ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.

Bergonzini C, Gregori A, Hagens TMS, van der Noord VE, van de Water B, Zweemer AJM, Coban B, Capula M, Mantini G, Botto A, Finamore F, Garajova I, McDonnell LA, Schmidt T, Giovannetti E, Danen EHJ. Bergonzini C, et al. Among authors: van der noord ve. J Exp Clin Cancer Res. 2024 Jan 2;43(1):4. doi: 10.1186/s13046-023-02879-8. J Exp Clin Cancer Res. 2024. PMID: 38163893 Free PMC article.

2

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.

van der Noord VE, van der Stel W, Louwerens G, Verhoeven D, Kuiken HJ, Lieftink C, Grandits M, Ecker GF, Beijersbergen RL, Bouwman P, Le Dévédec SE, van de Water B. van der Noord VE, et al. Breast Cancer Res. 2023 May 5;25(1):51. doi: 10.1186/s13058-023-01648-x. Breast Cancer Res. 2023. PMID: 37147730 Free PMC article.

3

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery.

van der Noord VE, van de Water B, Le Dévédec SE. van der Noord VE, et al. Cancers (Basel). 2022 Sep 7;14(18):4353. doi: 10.3390/cancers14184353. Cancers (Basel). 2022. PMID: 36139513 Free PMC article. Review.

4

Development of a Retinal-Based Probe for the Profiling of Retinaldehyde Dehydrogenases in Cancer Cells.

Koenders STA, Wijaya LS, Erkelens MN, Bakker AT, van der Noord VE, van Rooden EJ, Burggraaff L, Putter PC, Botter E, Wals K, van den Elst H, den Dulk H, Florea BI, van de Water B, van Westen GJP, Mebius RE, Overkleeft HS, Le Dévédec SE, van der Stelt M. Koenders STA, et al. Among authors: van der noord ve. ACS Cent Sci. 2019 Dec 26;5(12):1965-1974. doi: 10.1021/acscentsci.9b01022. Epub 2019 Dec 12. ACS Cent Sci. 2019. PMID: 31893226 Free PMC article.

5

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.

van der Noord VE, McLaughlin RP, Smid M, Foekens JA, Martens JWM, Zhang Y, van de Water B. van der Noord VE, et al. Sci Rep. 2019 Sep 16;9(1):13308. doi: 10.1038/s41598-019-49809-3. Sci Rep. 2019. PMID: 31527768 Free PMC article.

6

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.

McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B. McLaughlin RP, et al. Among authors: van der noord ve. Breast Cancer Res. 2019 Jul 1;21(1):77. doi: 10.1186/s13058-019-1161-9. Breast Cancer Res. 2019. PMID: 31262335 Free PMC article.

7

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.

Santegoets SJAM, de Groot AF, Dijkgraaf EM, Simões AMC, van der Noord VE, van Ham JJ, Welters MJP, Kroep JR, van der Burg SH. Santegoets SJAM, et al. Among authors: van der noord ve. Oncoimmunology. 2018 May 31;7(8):e1465166. doi: 10.1080/2162402X.2018.1465166. eCollection 2018. Oncoimmunology. 2018. PMID: 30221063 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page